Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center gives an overview of his presentation which focused on the use of talimogene laherparepvec and ipilimumab versus ipilimumab alone in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma
Advertisement